Cookie Error:

Cookies deactivated. To use all functions on this portal, for example the login, Cookies must be activated. Please activate Cookies in your browser settings.

News » UK
   
    Drucken Print 

Topping-out marks major milestone for Immunocore’s new HQ research lab at Milton Park

Representatives from MEPC, the manager and developer of Milton Park, and Immunocore Limited joined construction company Buckingham Group at a ceremonial ‘topping out’ event at 95 Park Drive, Immunocore’s new research laboratory building, on Tuesday 20th March. Immunocore, a soluble T cell receptor (TCR) company developing first-in-class biologics that have the potential to transform patient lives, is expanding its operations at Milton Park with an additional 53,000 sq ft purpose-built premises, which will help support the company’s continued growth. As well as 95 Park Drive, Immunocore, which has been based at Milton Park since 2000, currently occupies 165,000 sq ft of laboratory and office space.

.

“Today’s topping out is not only an exciting moment for Immunocore, it is also a milestone in our long-standing commitment to deliver state-of-the-art office and laboratory space for our occupiers. It further bolsters the reputation of Milton Park as a globally significant science and technology hub and part of the most fertile innovation economy in the UK,” said Speaking after the event, Philip Campbell, Commercial Director for MEPC at Milton Park.


From left to right: Darren Rodgerson, Immunocore, Facilities Director; Paul Nesbitt, Buckingham Group, Senior Project Manager, Paul Fry, Immunocore, CFO; Andrew Hotchkiss, Immunocore, CEO; Philip Campbell, MEPC, Commercial Director and Ben Leefield, MEPC, Senior Development Manager.